- 1 Title: A third vaccine dose equalizes the levels of effectiveness and immunogenicity of
- 2 heterologous or homologous COVID-19 vaccine regimens
- 4 Authors: Nicolas Guibert<sup>1</sup>, Kylian Trepat<sup>2,3</sup>, Bruno Pozzetto<sup>2,4</sup>, Laurence Josset<sup>2,5,6</sup>, Jean-
- 5 Baptiste Fassier<sup>1</sup>, Omran Allatif<sup>2</sup>, Kahina Saker<sup>3</sup> Karen Brengel-Pesce<sup>3</sup>, Thierry Walzer<sup>2</sup>\*,
- 6 Philippe Vanhems<sup>2,7</sup>\*, Sophie Trouillet-Assant<sup>2,3</sup>\* on behalf of Lyon-COVID study group<sup>\$</sup>

#### Affiliations

3

8

- 9 <sup>1</sup>Occupational Health and Medicine Department, Hospices Civils de Lyon, Université Claude Bernard
- Lyon1, Ifsttar, UMRESTTE, UMR T\_9405, Lyon University, Avenue Rockefeller, Lyon, France.
- <sup>2</sup>CIRI Centre International de Recherche en Infectiologie, Université de Lyon, Université Claude
- 12 Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-
- 13 Etienne, Lyon, France.
- <sup>3</sup>Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital,
- 15 Pierre-Bénite, 69310, France
- 16 <sup>4</sup>Laboratoire des Agents infectieux et d'Hygiène, University Hospital of Saint-Etienne, Saint-Etienne,
- 17 42055, France.
- 18 <sup>5</sup>Virology laboratory, Institut des Agents Infectieux, Laboratoire associé au Centre National de
- 19 Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-69004, Lyon, France.
- <sup>6</sup>GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004, Lyon,
- 21 France

26

29

- <sup>7</sup>Service D'Hygiène, Épidémiologie, Infectiovigilance et Prévention, Hôpital Édouard Herriot, Hospices
- 23 Civils de Lyon, Lyon, France
- 24 \*Senior authors equally contributed
- 25 \$Study group members are listed in the Acknowledgment section of the paper
- 27 **Correspondence**: Correspondence and requests for materials should be addressed to
- 28 <u>sophie.assant@chu-lyon.fr</u>
- 30 **Keywords:** SARS-CoV-2; vaccination; heterologous vaccine regimens; breakthrough infection;
- 31 healthcare workers; antibodies; neutralization

Abstract text:

32

33

34

35

36 37

38 39 **Backgroung :** To cope with the persistence of the Covid-19 epidemic and the decrease in antibody levels following vaccination, a third dose of vaccine has been recommended in the general population. However, several vaccine regimens had been used initially, and the heterologous ChadOx1-S/BNT162b2 regimen had shown better efficacy and immunogenicity than the homologous BNT162b2/BNT162b2 regimen.

- Aim: We wanted to determine if this benefit was retained after the third dose.
- 40 **Methods:** We combined an observational study of SARS-COV-2 infections among vaccinated 41 healthcare workers at the University-Hospital of Lyon, France, with an analysis of 42 immunological parameters before and after the third mRNA vaccine dose.
- Results: Following the second vaccine dose, heterologous vaccination regimens were more protective against infection than homologous regimens, but this was no longer the case after the third dose. RBD-specific IgG levels and serum neutralization capacity against different SARS-CoV-2 variants were higher after the third dose than after the second dose in the homologous regimen group, but not in the heterologous group.
- Conclusion: The advantage conferred by heterologous vaccination is lost after the third dose both in terms of protection and immunogenicity. Immunological measurements suggest that heterologous vaccination induces maximal immunity after the second dose, whereas the third dose is required to reach the same level in individuals with a homologous regimen.

#### Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

In response to the coronavirus disease pandemic, several vaccines were rapidly designed and administered to the population, inducing a protective immunity composed of both neutralizing antibodies and virus-specific T lymphocytes. As multiple vaccines were available, different heterologous combinations of prime/boost doses have been used in patients. This mixing of vaccines was motivated first by the necessary adaptation to limited vaccine supply, but also by the rare observation of vaccine-induced severe adverse reactions with some vaccines. Most studies have reported similar or higher immunogenicity following heterologous primary vaccination involving the Vaxzevria (ChAdOx1nCoV-19, AstraZeneca, Cambridge, United Kingdom) and mRNA vaccines Comirnaty (BNT162b2, BioNTechPfizer, Mainz, Germany/New York, United States) and Spikevax (mRNA-1273, Moderna, Cambridge, United States) compared to homologous vaccination [1-4]. For example, binding and neutralizing antibody titers were similar or greater in the heterologous boosted group compared to the homologous group [5,6]. In addition, we and others reported that the enhanced immunogenicity of the heterologous vaccination regimen was associated with a better protection against SARS-CoV-2 infection[2,7]. However, numerous studies have shown that the level of antibodies, and in particular those neutralizing the virus, gradually decreased following vaccination. This phenomenon, combined with the emergence of viral variants having acquired mutations in the spike viral protein making them less sensitive to vaccine antibodies, led health authorities to recommend the injection of a third booster dose. This booster dose was particularly important in immunosuppressed patients for whom vaccine efficacy was lower. Heterologous vaccine schedules of ChAdOx1-S priming and mRNA booster doses as both second and third doses were not associated with increased risk of serious adverse events compared with homologous mRNA vaccine schedules [8]. Recent reports demonstrated that most COVID-19 vaccines delivered as a third dose booster significantly enhanced both humoral and cellular anti-SARS-CoV-2 immunity [9]. Observational studies also suggest that a third dose significantly improves protection from symptomatic infection compared to two doses. A recent meta-analysis reported that heterologous and homologous three-dose regimens work comparably well in preventing covid-19 infections, even against different variants [10]. Nevertheless, a recent report has documented some differences in immunogenicity and protection according to vaccine schedule before third dose [11], suggesting that initial vaccination regimens could imprint spike-specific immunity in the long term, regardless of the booster dose.

To address this question, we compared spike-specific immunity and protection against infection conferred by second and third dose of mRNA vaccine in healthcare workers (HCWs) primed with either adenovirus-based ChAdOx1-S or COVID-19 mRNA vaccine.

#### Methods:

#### Prevalence of SARS-CoV-2 VOC

SARS-CoV-2 testing of HCWs was performed using routine diagnostic procedures in the Virology laboratory of the Hospices Civils de Lyon, and included: TMA (Aptima™ SARS-CoV-2 Assay (Hologic), LAMP (SARS-CoV-2 ID NOW™ (Abbott), and RT-qPCR with different kits (Cobas® 6800 SARS-CoV-2 assay (Roche), Panther Fusion SARS-CoV-2 assay (Hologic). To determine the prevalence of SARS-CoV-2 VOC in HCW, available positive samples with Ct<28 were sequenced using COVIDSeq (Illumina) as previously described [12]. Libraries were sequenced to 1 M paired-end reads (2x100 bp) and data were analyzed using the in-house sequent bioinformatic pipeline (available at https://github.com/genepii/seqmet). Clades and

lineages were determined on samples with genome coverage >90% using Nextclade and PangoLEARN, respectively.

### Ethical statement and cohort description

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Population of HCW from the hospital database included in the epidemiological investigation We extracted data from the occupational medicine database of the University Hospital of Lyon (Hospices Civils de Lyon), France. A total of 13489 HCWs working at Hospices civils de Lyon throughout the study period (12/15/21 03/21/22) were included. Only subjects who (i) had never contracted COVID-19, (ii) were primed with ChAdOx1-S-nCoV-19 or an mRNA vaccine and (iii) received the second or third dose of an RNA vaccine were included in the epidemiological analysis (Supplementary Figure 1). Breakthrough infections, documented by positive RT-PCR or antigenic tests and that occurred after the 15<sup>th</sup> of December 2021 and at least 7 days after vaccine injection were took into account to evaluate infection risk in different groups of subjects. Due to the mandatory SARS-CoV-2 vaccination for HCWs in France, we have no missing data regarding this variable. Moreover, the declaration of SARS-CoV-2 infection is compulsory for all staff to obtain daily allowances without loss of salary during the imposed quarantine. The use and analysis of data from the occupational health medical file were authorized after a regulatory declaration to the National Commission for Information Technology and Civil Liberties according to the reference methodology (declaration MR004 number 20-121 of April 30<sup>th</sup> 2020).

#### Population included in the immune response investigations

Eighty-eight naive HCWs for COVID-19 and vaccinated with BNT and/or ChAd and/or mRNA-1273 vaccines were included in a prospective longitudinal cohort study conducted at the Hospices Civils de Lyon. Blood sampling was performed before vaccination, before and 42 weeks after the second and the third dose of vaccine. The absence of previous SARS-CoV-2 infection was confirmed using the Abbott SARS-CoV-2 anti-N Ab total assay in all samples (Abbott Diagnostics, Abbott Park, Illinois, United States). Demographic characteristics and delays between doses are depicted in **Supplementary Table 1**.

## Measurement of IgG titers

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

Serum specimens were immediately stored at –80½°C after blood sampling. RBD-specific IgG antibodies were measured using bioMérieux Vidas SARS-CoV-2 IgG diagnosis kits, according to the manufacturers' recommendations. For standardization of these assays to the first World Health Organization international standard, the concentrations were transformed into binding antibody units per ml (BAU½ml<sup>-1</sup>) using the conversion factors provided by the manufacturers.

#### Live-virus neutralization experiments

A plaque reduction neutralization test (PRNT) was used for the detection and titration of neutralizing antibodies as previously described [13]. Neutralization was recorded if more than 50% of the cells present in the well were preserved. The neutralizing titer was expressed as the inverse of the higher serum dilution that exhibited neutralizing activity; a threshold of 20 was used (PRNT50 titer™≥™20). All experiments were performed with a subset of sera specimens collected longitudinally from 15 subjects in each group. The different viral strains that used sequenced deposited were were and at GISAID (https://www.gisaid.org/) (accession numbers EPI ISL 1707038 19A (B.38 lineage); EPI ISL 1904989 Delta (B.1.617.2 lineage); and EPI ISL 7608613 Omicron (B.1.1.529 lineage)).

#### Statistical analysis

The descriptive statistics generated appropriate figures and parameters according to type of variable (i.e. continuous or categorical). The comparisons between groups were done using the Chi-square test for categorical variables and non-parametric test or student T test according to the distribution for continuous variables. The cumulative probability of COVID-19 was based on the Kaplan-Meier survival analysis and survival distributions were compared using the LogRank test. A univariate and multivariate Cox proportional hazard model was performed to identify the determinants independently associated with onset of COVID-19 according to their hazard ratio (HR) and their 95% confidence interval (95% CI). All *P*-values were two-tailed. *P*2<20.05 was considered as statistically significant. For the immunological part, we used a multiple linear regression model, with adjustment variables (age or age groups, sex, delay, vaccination scheme).

#### Results

Vaccine effectiveness in HCWs

To compare the risk of SARS-CoV-2 infection following a second or third dose of COVID-19 mRNA vaccine (the Pfizer-BioNTech mRNA vaccine, BNT162b2, or the Moderna mRNA vaccine, mRNA-1273) in subjects who received a priming dose of ChAdOx1-S or BNT162b2 vaccine, we extracted data from the occupational medicine database of the University Hospital of Lyon (Hospices Civils de Lyon, HCL), France. We focused on individuals not previously infected with SARS-CoV-2 (PCR diagnosis) before vaccination to avoid any bias linked to hybrid immunity (Figure 1). Infection rates were monitored in HCWs after the second or the third booster dose in each group. We extracted SARS-CoV-2 infection incident events documented by positive antigenic or RT–PCR tests that occurred between December 15<sup>th</sup> 2021 and 21<sup>st</sup> March 2022. This period corresponds to the Omicron (lineage BA.1, Clade

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

21K) wave, succeeding to Delta (lineage B.1.1.529, Clades 21I and 21J), and preceding the Omicron sub-lineage BA.2 (Clade 21L) appearance and increase (Figure 2A-B). The proportion of SARS-CoV-2 variants of concern (VOC) determined by whole genome sequences in samples collected in HCWs working at Hospices Civils de Lyon during this period was: 70/834 (8.4%) 21J (Delta), 708/834 (84.9%) 21K (Omicron BA.1), and 56/834 (6.7%) 21L (Omicron BA.2). Figure 2C-D shows the cumulative incidence of breakthrough infections in each group. Following the second vaccine dose, heterologous vaccination regimens were more protective against infection compared to the homologous regimen group (Figure 2C). Indeed, after adjustment on age, sex and delay between last vaccination and the start of the study, individuals vaccinated with mRNA vaccines were twice as likely to be infected than those vaccinated with ChAdOx1-S followed by mRNA vaccine (adjusted hazard ratio of 1.88 [1.18-3.00], p-value =0.008, Figure 2E). After the third dose, the number of infections was lower than after the second dose in both vaccination groups, showing the benefit of the boost. Moreover, in the homologous group, the third dose achieved at least the same level of protection as in the heterologous group as demonstrated by the inversion of the infection incidence curves (adjusted hazard ratio of 0.86 [0.72 - 1.02], p-value =0.082, Figure 2F). We also conducted an analysis of the infection risk according to the parameters of vaccination, sex or age class. This analysis confirmed the importance of the vaccination schedule after the second dose but not after the third (Figure 2G-H). It also shows that in this cohort of vaccinated HCWs, middle-aged females had a higher risk of infection.

Analysis of immune response after heterologous and homologous vaccination

We then sought to compare the immunogenicity of the third dose in heterologous vs homologous vaccination groups. For this, we took advantage of the *Covid-Ser* cohort that we

previously described and which includes a subset of voluntary healthcare workers in whom anti-SARS-CoV-2 immunity is measured longitudinally over time (Figure 3)[2]. We formed groups who had received a homologous or heterologous vaccination regimen and who had received a third dose of mRNA vaccine (Table 1).

	HCWs primed with BNT (homologous) n=58	HCWs primed with ChadOx (heterologous) n=30	p.adj
Male sex. n	11	6	>0.9999
Age. Year. Median [IQR]	50.50 [41.00-59.00]	38.00 [30.50-41.00]	<0.0001
Body Mass Index *. n	55	29	
Median [IQR]	24.22 [22.12-29.72]	20.94 [20.06-23.88]	0.0077
Delay between first and	28 [28-30]	85 [84-85]	<0.0001
second dose. Day. Median			
[IQR]			
Delay between second	266 [245-284]	206 [195-213]	<0.0001
and third dose. Day.			
Median [IQR]			
Third dose Moderna. n	5	3	>0.9999
Presence of comorbidity. n	29	10	0.5828
Description of			
comorbidities			
Hypertension. n	2	0	>0.9999
Diabetes. n	2	0	>0.9999
Cancer. n	1	0	>0.9999
Hypothyroidy. n	4	1	>0.9999
Rheumatic diseases. n	1	0	>0.9999
Chronic respiratory	4	0	0.7200
problems. n			
Others. n	5	0	0.5480
Currently smoker. n	14	6	>0.9999
Alcohol consumption. n	8	6	>0.9999

 Table 1: Clinical characteristics of patients in the Covid-Ser study (immunological analysis)

For alcohol consumption, this was defined as consumption at least once a week. Wilcoxon-Mann–Whitney two-sided tests were used for quantitative variables and Chi-square or Fisher were used for qualitative variables when appropriate. Adjusted P values were calculated using the Benjamini–Hochberg method.

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

Subsequently, we measured the increase in anti-RBD IgG antibody levels four weeks after the third dose in both groups. No significant difference was observed (p=0.14) (Figure 4A). We then evaluated the neutralization capacity of serum antibodies against SARS-CoV-2 variants 19A, Delta and Omicron four weeks after the third dose. No significant difference in neutralization was observed between the homologous and heterologous schedules (19A: median [IQR] 960 [320-1920] vs. 640 [320-1920]; Delta: 240 [120-480] vs. 320 [160-960]; Omicron: 160 [60-640] vs. 160 [80-480], respectively) (Figure 4B). Moreover the anti-RBD IgG level is not different in the two groups after the third dose (p=0.18) (Figure 4C). Data in Figure 2 show that the heterologous ChAdOx1-S/COVID-19 mRNA vaccine combination confers better protection against SARS-COV-2 infection than the homologous COVID-19 mRNA vaccines combination, but that the third dose equalizes the efficacy of both vaccine regimens. To understand why the advantage of heterologous vaccination is no longer observed after the third dose, we compared humoral immunity four weeks after the second and after the third dose in each group. In subjects vaccinated according to the homologous regimen, the anti-RBD IgG level measured 4 weeks post second dose was significantly lower (p<0.0001) than that measured post third dose (1490 [969-2994] BAU/mL, 3336 [1795-4491] BAU/mL respectively) (Figure 4D) whereas in subjects vaccinated according to a heterologous scheme, no difference was observed (2277 [1520-3400] BAU/mL vs 2242 [1321-3602] BAU/mL respectively) (Figure 4E). In addition, for the homologous vaccine group, the antibody neutralizing capacity 4 weeks post third dose was at least 3 times higher than that observed 4 weeks post second dose (at least p<0.01). In contrast, in heterologous vaccinated individuals, no benefit in neutralizing capacity against 19A and Delta at 4 weeks post third dose was observed. Only the neutralizing capacity of the total antibodies 4 weeks post third dose against Omicron increased 2-fold compared to that 4

weeks post second dose (p<0.01) (**Figure 4F-G**). Of note, there is no difference of anti-SARS-CoV-2 IgG level 4 weeks post third dose between HCWs boosted with BNT162b2 (n=80) or mRNA-1273 (n=8) vaccine (p=0.30).

#### Discussion

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

We previously showed that the heterologous ChAdOx1-S/BNT162b2 combination confers better protection against SARS-CoV-2 infection than the homologous BNT162b2/BNT162b2 combination in a real-world observational study conducted in HCWs [2]. Both combinations induced strong anti-spike antibody responses but serum specimens from heterologous vaccinated individuals displayed a stronger neutralizing activity, regardless of the SARS-CoV-2 variant [14]. Here, we asked whether the advantage conferred by the heterologous regimen is conserved after a booster dose of mRNA-based COVID-19 vaccine. Our results show that (i) the third dose with an mRNA vaccine equalizes the levels of effectiveness of heterologous or homologous COVID-19 vaccine regimens and (ii) that serum neutralization capacity against different SARS-CoV-2 variants is comparable four weeks after the boost in both groups. Indeed, the third vaccine dose does not increase antibody levels and neutralization capacity beyond those observed one month after the second dose in the heterologous group, which suggests that a maximal immunity level one month post vaccination is already reached after the second dose in this group and that it cannot be boosted further, at least with an mRNA-based vaccine. While we cannot exclude that a shorter delay between the second and third doses would have a different impact in heterologous vs homologous groups, our results are in line with those of Accorsi et al. who showed that a single booster dose of an mRNA Covid-19 vaccine in individuals who received primary vaccination with a single-dose of adenovirus-based vaccine Ad26.COV2.S, provided

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

protection close to that of the three-dose mRNA vaccine regimen [15]. In addition, Behrens et al. reported that inferior SARS-CoV-2 specific immune responses following homologous ChAdOx1-S / ChAdOx1-S vaccination compared to ChAdOx1-S /BNT162b2 can be compensated by heterologous BNT vaccination as third dose [16]. In our study, only the neutralization of the Omicron variant was slightly better one month after the third dose in the heterologous regimen compared to the second dose. The significance of this result is not clear since the neutralization of the other variants was not changed. More largely, our results address the question of the number of vaccine boosts that are needed to reach the maximal immunity level against SARS-CoV-2, including its numerous variants. We confirm that, using the heterologous combination performed in our study, a single boost is enough to reach this plateau. By contrast, the homologous scheme using an mRNA vaccine needs two boosts for reaching the same level of protection. Of course, this maximum immunity is temporary and decreases with time, which makes the third dose necessary in the heterologous group as well. The recent study of Regev-Yochay et al. that evaluated the benefit of a third boost in an homologous mRNA immunization scheme suggests that a maximum immunity is reached after the third dose with homologous mRNA vaccination. The fourth mRNA vaccine dose seems to be able to restore the level of immunity, but does not quantitatively and qualitatively improve the humoral immunity conferred by the first 3 doses [17]. Surprisingly, our data highlighted a higher risk of infection in women between 30 and 50 years compared to older HCW. This group of individuals mainly corresponds to active nursing staff with higher exposure to pathogens. Indeed, in the Lyon University hospital, the pattern of contacts (frequency and duration) between nurses and patients and within nurses is superior than for other professionals [18], and this pattern could result in a higher exposure

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

to pathogens, as previously reported in a study of nosocomial influenza spreading at the hospital [19]. Obviously, this higher exposure of middle-aged women is specific to the HCW community and may not apply to the general population. Some limitations of the present study should be acknowledged. First, these results were obtained from observational data and not from a randomized clinical trial. As a result there were some inherent differences between the compared groups. For example subjects vaccinated with a heterologous schedule were on average younger than those vaccinated with a homologous schedule. This difference is explained by the recommendations for vaccination according to which individuals under 55 years of age who received a first dose of ChAdOx1-S should receive a boost of COVID-19 mRNA vaccine. Yet, our statistical analysis did not show a significant impact of age in infection risk or vaccine-induced immune parameters. Second, the HCWs might slightly differ from the general population since they exhibit repeated exposures to SARS-CoV-2, together with close monitoring regarding vaccine coverage and COVID-19 incidence. Third, in our study, the advantage of the heterologous regimen observed after the second dose may be impacted by the delay between the first and second dose which was only of 4 weeks between the first two doses in the homologous scheme. A study by Payne et al. reported that an extended delay of 10 weeks between the first two doses of BNT162b2 allowed the development of better humoral immunity [20]. Fourth, the present study was limited to HCWs having no history of SARS-CoV-2 infection prior to vaccination. The benefit of booster dose of mRNA vaccine in patients primed with ChAdOx1-S or mRNA vaccine would need further investigations in people previously infected by different variants. Finally, even if HCWs were heavily tested during the monitoring period of our study, asymptomatic infections may have remained unnoticed.

Taken together, our data provide evidence to understand the number of vaccine boosts that are needed to reach the maximal immunity level against SARS-CoV-2 in heterologous or homologous vaccine scheme. More studies will be needed to determine if another vaccine type should be given to boost even further SARS-CoV-2 immunity.

#### Ethical statements

For the Covid-Ser study, clinical data were recorded by a trained clinical research associate using Clinsight software (v.Csonline 7.5.720.1). Written informed consent was obtained from all participants. Ethics approval was obtained from the national review board for biomedical research in April 2020 (Comité de Protection des Personnes Sud Méditerranée I, Marseille, France; ID RCB 2020-A00932-37), and the study was registered at Clinical Trials.gov (NCT04341142).

References

312

- 313 1. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and
- reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med, 2021;
- 315 27(9):1530<sup>2</sup>5.
- 2. Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, et al. Immunogenicity
- and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature, 2021;
- 318 600(7890):701 26.
- 319 3. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
- 320 immunogenicity of heterologous versus homologous prime-boost schedules with an
- adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind,
- 322 randomised, non-inferiority trial. The Lancet, 2021; 398(10303):856 269.
- 4. Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A, et al. Comparative
- immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and
- BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat
- 326 Commun. 2022; 13(1):4710.
- 327 5. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety,
- reactogenicity, and immunogenicity of homologous and heterologous prime-boost
- immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet
- 330 Respir Med. 2021; 9(11):1255 265.
- 6. Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K,
- Sapsutthipas S, et al. Immunogenicity and reactogenicity against the SARS-CoV-2 variants
- following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and
- BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in
- healthy Thai adults. Human Vaccines & Immunotherapeutics. 2022; 2091865.
- 7. Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of Homologous or
- Heterologous Covid-19 Boosters in Veterans. N Engl J Med. 2022; 386(14):1375 27.
- 8. Andersson NW, Thiesson EM, Laursen MV, Mogensen SH, Kjær J, Hviid A. Safety of
- heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-
- 340 1273 vaccines: nationwide cohort study. BMJ. 2022; 378:e070483.
- 341 9. Lustig Y, Gonen T, Meltzer L, Gilboa M, Indenbaum V, Cohen C, et al. Superior
- immunogenicity and effectiveness of the third compared to the second BNT162b2
- 343 vaccine dose. Nat Immunol. 2022; 23(6):94026.
- 344 10. Au WY, Cheung PPH. Effectiveness of heterologous and homologous covid-19 vaccine
- regimens: living systematic review with network meta-analysis. BMJ. 2022; 377:e069989.
- 11. Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of
- immunogenicity after seven COVID-19 vaccines given as third dose boosters following
- two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the
- 349 COV-BOOST trial. J Infect. 2022; 795 2813.

350 12. Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant 351 circulation, France, December 2021 - February 2022 | medRxiv. DOI: 352 10.1101/2022.03.24.22272871v1 353 13. Saade C, Gonzalez C, Bal A, Valette M, Saker K, Lina B, et al. Live virus neutralization 354 testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 355 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerg Microbes Infect. 2021; 10(1):14992502. 14. Lee HK, Go J, Sung H, Kim SW, Walter M, Knabl L, et al. Heterologous ChAdOx1-356 357 BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses 358 that includes Omicron. iScience. 2022; 25(6):104473. 359 15. Accorsi EK, Britton A, Shang N, Fleming-Dutra KE, Link-Gelles R, Smith ZR, et al. 360 Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. New 361 England Journal of Medicine. 2022; 386(25):243325. 362 Behrens GMN, Barros-Martins J, Cossmann A, Ramos GM, Stankov MV, Odak I, et al. 363 BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Commun. 2022; 364 365 13(1):4872. 366 17. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy 367 of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med. 2022; 368 386(14):1377280. 369 18. Vanhems P, Barrat A, Cattuto C, Pinton JF, Khanafer N, Régis C, et al. Estimating Potential 370 Infection Transmission Routes in Hospital Wards Using Wearable Proximity Sensors. 371 Viboud C, éditeur. PLoS ONE. 2013; 8(9):e73970. 372 19. Voirin N, Payet C, Barrat A, Cattuto C, Khanafer N, Régis C, et al. Combining high-373 resolution contact data with virological data to investigate influenza transmission in a 374 tertiary care hospital. Infect Control Hosp Epidemiol. 2015; 36(3):254260. 375 20. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity 376 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;

377

378

184(23):5699-5714.e11.

Figure legends

379

380

381

382

383

384

385

399

401

**Figure 1:** Flow chart of the epidemiological study.

The flow chart indicates how individuals with two (left) or three vaccination doses (right)

were selected from the total HCW population according to the indicated criteria of


exclusion.


- Figure 2: The superior efficacy of heterologous vaccination is lost after the third vaccine dose
- 386 (A) Weekly SARS-CoV-2 testing (n= 2,113 positive samples / 7,863 negative samples) and (B)
- Variant of concern (VOC) circulation (B) among HCW (n=834 samples with whole genome
- sequence (WGS) between Dec 15<sup>th</sup>, 2021 and March 21<sup>st</sup>, 2022 at Lyon University Hospitals.
- 389 (C-D) Graphs show the cumulative probability of COVID-19 infection within 100 days after a
- $2^{nd}$  (C) or a  $3^{rd}$  (D) mRNA vaccine dose in health care workers at Lyon university hospital
- 391 primed with BNT162b2 (blue line, homologous vaccination, 3074 and 6436 HCWs
- respectively) or ChAdOx1-S vaccine (brown line, heterologous vaccination, 328 and 1160
- 393 HCWs respectively). P-value was calculated using Logrank test. (E-F) Forest Plots depict
- 394 multivariate Cox proportional hazard ratio (IC95%) for COVID-19 infection after a 2<sup>nd</sup> (E) or a
- 395 3<sup>rd</sup> (F) mRNA vaccine dose in health care workers. Hazard Ratio (HRs) were calculated with
- 396 the HR of 1.0 of the reference stratum, references were indicated for all comparisons. All
- 397 SARS-CoV-2 infection events documented by positive SARS-CoV-2 RT-PCR or antigenic test
- were recorded by the service of occupational medicine, Hospices Civils de Lyon.
- 400 **Figure 3**: Design of the "Covid-Ser" study
- 402 Figure 4: The booster dose equalizes the levels of immunogenicity of heterologous or
- 403 homologous vaccine regimens
- Sera from naïve HCWs vaccinated primed with the BNT162b2 (n=58) or ChadOx1-S vaccine,
- 405 n=30) and who received an mRNA vaccine for 2<sup>nd</sup> and 3<sup>rd</sup> dose were selected. (A) RBD-
- 406 specific IgG levels were quantified just before and four weeks post booster (third) dose.
- 407 Concentrations are expressed in binding antibody units per ml (BAU/ml), and data show the
- 408 difference in RBD-specific IgG levels between the two time-points (missing value for pre-
- vaccination time point for 11 and 4 patients vaccinated with homologous and heterologous
- 410 regimen respectively). (B) A subset of 15 sera from both groups four weeks after the third

dose were assayed in duplicate for their capacity to neutralize infection of Vero E6 cells by different SARS-CoV-2 strains, as indicated. (C) Comparison of serum RBD-specific IgG levels 4 weeks after the 3<sup>rd</sup> dose between homologous and heterologous vaccine recipients (D-E) Serum RBD-specific IgG levels were measured 4 weeks after the 2<sup>nd</sup> or after the 3<sup>rd</sup> dose in the homologous (D) or heterologous (E) vaccine recipients. (F-G) Comparison of the neutralizing capacity of total antibodies collected 4 weeks after the 2<sup>nd</sup> or after the 3<sup>rd</sup> dose in the homologous (F) or in the heterologous (G) vaccine group (n=15 for each group). The dashed lines represent the limit of detection (20 in PRNT<sub>50</sub>). In all graphs, data are represented as box-and-whiskers plots using the Tukey method which show median (horizontal line inside the box), interquartile (25%-75% - upper and lower horizontal lines of the box), and each dot corresponds to one subject. Statistics were calculated using a multiple linear regression model with adjustment variables (age and sex, and when appropriate delay between second and third dose).


# Two doses of vaccines

# Three doses of vaccines








Figure\_3



# Naïve vaccinated subjects









Adenoviral vaccine (ChAdOx1-S)



mRNA vaccine (BNT162b2 or mRNA-1273)

